Label: PRAVASTATIN SODIUM tablet

  • NDC Code(s): 0093-0771-10, 0093-0771-98, 0093-7201-10, 0093-7201-98, view more
    0093-7202-10, 0093-7202-98
  • Packager: Teva Pharmaceuticals USA, Inc.
  • Category: HUMAN PRESCRIPTION DRUG LABEL

Drug Label Information

Updated August 31, 2022

If you are a healthcare professional or from the pharmaceutical industry please visit this version.

  • HIGHLIGHTS OF PRESCRIBING INFORMATION
    These highlights do not include all the information needed to use PRAVASTATIN SODIUM TABLETS safely and effectively. See full prescribing information for PRAVASTATIN SODIUM TABLETS.

    PRAVASTATIN SODIUM tablets, for oral use
    Initial U.S. Approval: 1991

    RECENT MAJOR CHANGES

    Contraindications, Pregnancy and Lactation Removed (4)                                                                                 

    05/2022

    Warnings and Precautions,

    Immune-Mediated Necrotizing Myopathy Updated (5.2)                                                                                     

    05/2022

    INDICATIONS AND USAGE

    Pravastatin sodium is an HMG-CoA reductase inhibitor (statin) indicated (1):

    • To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD).
    • To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD.
    • As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia.
    • As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH).
    • As an adjunct to diet for the treatment of adults with:
      • Primary dysbetalipoproteinemia.
      • Hypertriglyceridemia.

    DOSAGE AND ADMINISTRATION

    • Take orally once daily at any time of the day, with or without food (2.1).
    • For patients that require a high-intensity statin or are unable to achieve their LDL-C goal receiving pravastatin sodium tablets 80 mg daily, prescribe alternative LDL-C-lowering treatment (2.1).
    • Assess LDL-C when clinically appropriate, as early as 4 weeks after initiating pravastatin sodium tablets, and adjust the dosage if necessary (2.1).
    • Adults: recommended starting dosage is pravastatin sodium tablets
      40 mg to 80 mg once daily. (2.2)
    • Pediatric Patients (2.3):
      • aged 8 to 13 years, the recommended dosage is 20 mg once daily.
      • aged 14 to 18 years, the recommended starting dosage is
        40 mg once daily.
    • Severe renal impairment: recommended starting dosage is pravastatin sodium 10 mg once daily. Use another pravastatin sodium product to initiate dosing. Recommended maximum pravastatin sodium tablets dosage is 40 mg once daily. (2.4)
    • See full prescribing information for dosage modifications due to drug interactions (2.5,7).

    DOSAGE FORMS AND STRENGTHS

    • Tablets: 10 mg, 20 mg, and 40 mg of pravastatin sodium. (3)

    CONTRAINDICATIONS

    • Hypersensitivity to pravastatin or any excipient in pravastatin sodium tablets (4)
    • Acute liver failure or decompensated cirrhosis (4, 5.3)

    WARNINGS AND PRECAUTIONS

    • Myopathy and Rhabdomyolysis: Risk factors include age 65 years or greater, uncontrolled hypothyroidism, renal impairment, concomitant use with certain other drugs, and higher pravastatin dosage. Discontinue pravastatin if markedly elevated CK levels occur or myopathy is diagnosed or suspected. Temporarily discontinue pravastatin in patients experiencing an acute or serious condition at high risk of developing renal failure secondary to rhabdomyolysis. Inform patients of the risk of myopathy and rhabdomyolysis when starting or increasing pravastatin dosage. Instruct patients to promptly report unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever. (5.1, 7.1, 8.5, 8.6)
    • Immune-Mediated Necrotizing Myopathy (IMNM): Rare reports of IMNM, an autoimmune myopathy, have been reported. Discontinue pravastatin if IMNM is suspected (5.2).
    • Hepatic Dysfunction: Increases in serum transaminases have occurred, some persistent. Rare reports of fatal and non-fatal hepatic failure have occurred. Consider testing liver enzymes before initiating therapy and as clinically indicated thereafter. If serious hepatic injury with clinical symptoms and/or hyperbilirubinemia or jaundice occurs, promptly discontinue (5.3).

    ADVERSE REACTIONS

    In short-term clinical trials, the most commonly reported adverse reactions (≥2% and greater than placebo) were: musculoskeletal pain, nausea/vomiting, upper respiratory infection, diarrhea, and headache. (6.1)

     

    To report SUSPECTED ADVERSE REACTIONS, contact Teva at 1-888-838-2872 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

    DRUG INTERACTIONS

    • See full prescribing information for details regarding concomitant use of pravastatin sodium tablets with other drugs that increase the risk of myopathy and rhabdomyolysis. (2.5, 7.1)
    • Bile Acid Sequestrants: in patients taking a bile acid sequestrant, administer pravastatin sodium tablets at least 1 hour before or at least 4 hours after the bile acid sequestrant (7.2)

    USE IN SPECIFIC POPULATIONS

    • Pregnancy: May cause fetal harm (8.1)
    • Lactation: Breastfeeding not recommended during treatment with pravastatin sodium tablets (8.2)

    See 17 for PATIENT COUNSELING INFORMATION.

    Revised: 8/2022

  • Table of Contents
  • 1 INDICATIONS AND USAGE

    Pravastatin sodium tablets are indicated:

    • To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD).
    • To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD.
    • As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia.
    • As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH).
    • As an adjunct to diet for the treatment of adults with:
      • Primary dysbetalipoproteinemia.
      • Hypertriglyceridemia.
  • 2 DOSAGE AND ADMINISTRATION

    2.1 Important Dosage and Administration Information

    • Take pravastatin sodium tablets orally once daily as a single dose at any time of the day, with or without food.
    • For patients that require a high-intensity statin or are unable to achieve their LDL-C goal receiving pravastatin sodium tablets 80 mg daily, prescribe alternative LDL-C-lowering treatment.
    • Assess LDL-C when clinically appropriate, as early as 4 weeks after initiating pravastatin sodium tablets, and adjust the dosage if necessary.

    2.2 Recommended Dosage in Adult Patients

    The recommended starting dosage is pravastatin sodium tablets 40 mg to 80 mg once daily.

    2.3 Recommended Dosage in Pediatric Patients 8 Years of Age and Older with HeFH

    • In pediatric patients aged 8 to 13 years, the recommended dosage is pravastatin sodium tablets 20 mg once daily.
    • In pediatric patients aged 14 to 18 years, the recommended starting dosage is pravastatin sodium tablets
      40 mg once daily.

    2.4 Recommended Dosage in Patients with Renal Impairment

    • In patients with severe renal impairment, the recommended starting dosage is pravastatin sodium 10 mg once daily. The maximum recommended dosage of pravastatin sodium tablets in patients with severe renal impairment is 40 mg once daily [see Clinical Pharmacology (12.3)].
    • The recommended dosage of pravastatin sodium tablets for patients with mild or moderate renal impairment is the same as patients with normal renal function.

    2.5 Dosage and Administration Modifications Due to Drug Interactions

    • In patients taking a bile acid sequestrant, administer pravastatin sodium tablets at least 1 hour before or 4 hours after the bile acid sequestrant [see Drug Interactions (7.2)].
    • Concomitant use of pravastatin sodium tablets with the following drugs requires dosage modifications of pravastatin sodium tablets [see Warnings and Precautions (5.1) and Drug Interactions (7.1)]:
      • Cyclosporine

      In patients taking cyclosporine, the recommended starting dosage is pravastatin sodium 10 mg once daily. The maximum recommended dosage of pravastatin sodium tablets in patients taking cyclosporine is 20 mg once daily.

      • Clarithromycin and Erythromycin

      The maximum recommended dosage is pravastatin sodium tablets 40 mg once daily.

  • 3 DOSAGE FORMS AND STRENGTHS

    Pravastatin sodium tablets, USP are supplied as:

    • 10 mg of pravastatin sodium: Pink, unscored, round tablet, debossed “TEVA” on one side and “771” on the other side.
    • 20 mg of pravastatin sodium: Light-yellow, unscored, round tablet, debossed “TEVA” on one side and “7201” on the other side.
    • 40 mg of pravastatin sodium: Light-green, unscored, round tablet, debossed “TEVA” on one side and “7202” on the other side.
  • 4 CONTRAINDICATIONS

    • Acute liver failure or decompensated cirrhosis [see Warnings and Precautions (5.3)].
    • Hypersensitivity to any pravastatin or any excipients in pravastatin sodium tablets.
  • 5 WARNINGS AND PRECAUTIONS

    5.1 Myopathy and Rhabdomyolysis

    Pravastatin may cause myopathy and rhabdomyolysis. Acute kidney injury secondary to myoglobinuria and rare fatalities have occurred as a result of rhabdomyolysis in patients treated with statins, including pravastatin. Myopathy, defined as muscle aching or muscle weakness in conjunction with increases in creatine phosphokinase (CK) to greater than 10 times the upper limit of normal (ULN), occurred <0.1% in pravastatin-treated patients in clinical trials.

    Risk Factors for Myopathy

    Risk factors for myopathy include age 65 years or greater, uncontrolled hypothyroidism, renal impairment, concomitant use with certain other drugs (including other lipid-lowering therapies), and higher pravastatin dosage [see Drug Interactions (7.1)].

    Steps to Prevent or Reduce the Risk of Myopathy and Rhabdomyolysis

    Pravastatin is not recommended in patients taking gemfibrozil [see Drug Interactions (7)]. There are pravastatin dosage restrictions for patients taking cyclosporin and select macrolide antibiotics [see Dosage and Administration (2.5)]. The following drugs when used concomitantly with pravastatin may also increase the risk of myopathy and rhabdomyolysis: niacin, fibrates, and colchicine [see Drug Interactions (7)].

    Discontinue pravastatin if markedly elevated CK levels occur or myopathy is diagnosed or suspected. Muscle symptoms and CK increases may resolve if pravastatin is discontinued. Temporarily discontinue pravastatin in patients experiencing an acute or serious condition at high risk of developing renal failure secondary to rhabdomyolysis, e.g., sepsis; shock; severe hypovolemia; major surgery; trauma; severe metabolic, endocrine, or electrolyte disorders; or uncontrolled epilepsy.

    Inform patients of the risk of myopathy and rhabdomyolysis when starting or increasing the pravastatin dosage. Instruct patients to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by malaise or fever.

    5.2 Immune-Mediated Necrotizing Myopathy

    There have been rare reports of immune-mediated necrotizing myopathy (IMNM), an autoimmune myopathy, associated with statin use, including reports of recurrence when the same or a different statin was administered. IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. Additional neuromuscular and serologic testing may be necessary. Treatment with immunosuppressive agents may be required. Discontinue pravastatin if IMNM is suspected.

    5.3 Hepatic Dysfunction

    Increases in serum transaminases have been reported with use of pravastatin [see Adverse Reactions (6.1)]. In most cases, these changes appeared soon after initiation, were transient, were not accompanied by symptoms, and resolved or improved on continued therapy or after a brief interruption in therapy. Persistent increases to more than three times the ULN in serum transaminases have occurred in approximately 1% of patients receiving either pravastatin or placebo in clinical studies. Marked persistent increases of hepatic transaminases have also occurred with pravastatin. There have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins, including pravastatin.

    Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.

    Consider liver enzyme testing before pravastatin initiation and when clinically indicated thereafter. Pravastatin is contraindicated in patients with acute liver failure or decompensated cirrhosis [see Contraindications (4)]. If serious hepatic injury with clinical symptoms and/or hyperbilirubinemia or jaundice occurs, promptly discontinue pravastatin.

    5.4 Increases in HbA1c and Fasting Serum Glucose Levels

    Increases in HbA1c and fasting serum glucose levels have been reported with statins, including pravastatin. Optimize lifestyle measures, including regular exercise, maintaining a healthy body weight, and making healthy food choices.

  • 6 ADVERSE REACTIONS

    The following important adverse reactions are described below and elsewhere in the labeling:

    6.1 Clinical Trials Experience

    Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.

    In pravastatin placebo-controlled clinical trials, 1,313 patients (age range 20 to 76 years, 32% women, 93.5% White, 5% Black, 0.9% Hispanic, 0.4% Asian, 0.2% Other) with a median treatment duration of 14 weeks, 3.3% of patients on pravastatin and 1.2% patients on placebo discontinued due to adverse reactions (regardless of causality). The most common adverse reactions that led to treatment discontinuation and occurred at an incidence greater than placebo were: hepatic transaminase elevations, nausea, anxiety/depression, and dizziness.

    Adverse reactions (regardless of causality) reported in ≥2% of pravastatin-treated patients in placebo-controlled trials of up to 8 months duration are identified in Table 1:

    Table 1: Adverse Reactions in ≥ 2% of Patients Treated with Pravastatin (Any Dose) and at an Incidence Greater Than Placebo in Short-Term Placebo-Controlled Trials

    % Placebo
    N=411

    % Any Dose
    N=902

    Nausea/Vomiting

    7.1

    7.4

    Diarrhea

    5.6

    6.7

    Headache

    4.6

    6.3

    Upper Respiratory Infection

    5.8

    5.9

    Angina Pectoris

    3.4

    4.5

    Rash

    1.4

    4.5

    CPK Increased

    3.6

    4.1

    Dizziness

    3.4

    3.5

    ALT Increased

    1.2

    2.9

    Chest Pain

    1.9

    2.7

    Cough

    1.7

    2.5

    Myalgia

    1.2

    2.3

    Influenza

    0.7

    2.0

    g-GT Increased

    1.2

    2.0

    Adverse Reactions (regardless of causality)

    The safety and tolerability of pravastatin at a dose of 80 mg in 2 controlled trials with a mean exposure of 8.6 months was similar to that of pravastatin at lower doses except that 4 out of 464 patients taking 80 mg of pravastatin had a single elevation of CK >10 times ULN compared to 0 out of 115 patients taking 40 mg of pravastatin.

    In pravastatin placebo-controlled clinical trials, 21,483 patients (age range 24 to 75 years, 10.3% women, 52.3% White, 0.8% Black, 0.5% Hispanic, 0.1% Asian, 0.1% Other, 46.1% not recorded) had a median treatment duration of 261 weeks.

    Adverse reactions (regardless of causality) were pooled from 7 double-blind, placebo-controlled trials (West of Scotland Coronary Prevention Study [WOS]; Cholesterol and Recurrent Events study [CARE]; Long-term Intervention with Pravastatin in Ischemic Disease study [LIPID]; Pravastatin Limitation of Atherosclerosis in the Coronary Arteries study [PLAC I]; Pravastatin, Lipids and Atherosclerosis in the Carotids study [PLAC II]; Regression Growth Evaluation Statin

    Study [REGRESS]; and Kuopio Atherosclerosis Prevention Study [KAPS]) involving a total of 10,764 patients treated with pravastatin 40 mg and 10,719 patients treated with placebo. Patients were exposed to pravastatin for a mean of 4.0 to 5.1 years in WOS, CARE, and LIPID and 1.9 to 2.9 years in PLAC I, PLAC II, KAPS, and REGRESS. Adverse reactions (regardless of causality) occurring in ≥5% of patients treated with pravastatin in these studies are identified in Table 2:

    Table 2: Adverse Reactions in ≥5% of Patients Treated with Pravastatin 40 mg and at an Incidence Greater than Placebo in Long-Term Placebo-Controlled Trials

    Placebo
    (N=10,719)
    % of patients

    Pravastatin
    (N=10,764)
    % of patients

    Musculoskeletal Pain

    24.4

    24.9

    Upper Respiratory Tract Infection

    20.2

    21.2

    Musculoskeletal Traumatism

    9.6

    10.2

    Chest Pain

    9.8

    10.0

    Influenza

    9.0

    9.2

    Fatigue

    7.8

    8.4

    Cough

    7.4

    8.2

    Dizziness

    6.6

    7.3

    Rash (including dermatitis)

    7.1

    7.2

    Sinus Abnormality

    6.7

    7.0

    Muscle Cramp

    4.6

    5.1

    Adverse Reactions (regardless of causality)

    No new adverse reactions were identified in a study of pediatric patients with HeFH.

    Laboratory Abnormalities

    Increases in ALT, AST values and CK have been observed.

    Transient, asymptomatic eosinophilia has been reported. Eosinophil counts usually returned to normal despite continued therapy. Anemia, thrombocytopenia, and leukopenia have been reported with statins.


    6.2 Postmarketing Experience

    The following adverse reactions have been identified during postapproval use of pravastatin. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

    Musculoskeletal: myopathy, rhabdomyolysis, tendon disorder, polymyositis, immune-mediated necrotizing myopathy associated with statin use.

    Nervous System: dysfunction of certain cranial nerves (including alteration of taste, impairment of extraocular movement, facial paresis), peripheral nerve palsy. Rare postmarketing reports of cognitive impairment (e.g., memory loss, forgetfulness, amnesia, memory impairment, confusion) associated with statin use. Cognitive impairment was generally nonserious, and reversible upon statin discontinuation, with variable times to symptom onset (1 day to years) and symptom resolution (median of 3 weeks).

    Hypersensitivity: anaphylaxis, angioedema, lupus erythematosus-like syndrome, polymyalgia rheumatica, dermatomyositis, vasculitis, purpura, hemolytic anemia, positive ANA, ESR increase, arthritis, arthralgia, asthenia, photosensitivity, chills, malaise, toxic epidermal necrolysis, erythema multiforme (including Stevens-Johnson syndrome).

    Gastrointestinal: abdominal pain, constipation, pancreatitis, hepatitis (including chronic active hepatitis), cholestatic jaundice, fatty change in liver, cirrhosis, fulminant hepatic necrosis, hepatoma, fatal and non-fatal hepatic failure.

    Dermatologic: a variety of skin changes (e.g., nodules, discoloration, dryness of mucous membranes, changes to hair/nails), lichen planus.

    Renal: urinary abnormality (including dysuria, frequency, nocturia).

    Respiratory: dyspnea, interstitial lung disease.

    Psychiatric: nightmare.

    Reproductive: gynecomastia.

    Laboratory Abnormalities: liver function test abnormalities, thyroid function abnormalities.

  • 7 DRUG INTERACTIONS

    7.1 Drug Interactions that Increase the Risk of Myopathy and Rhabdomyolysis with Pravastatin

    Pravastatin is a substrate of the transport protein OATP1B1. Pravastatin plasma levels can be significantly increased with concomitant administration of inhibitors of OATP1B1. Table 3 includes a list of drugs that increase the risk of myopathy and rhabdomyolysis when used concomitantly with pravastatin and instructions for preventing or managing them [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].

    Table 3: Drug Interactions that Increase the Risk of Myopathy and Rhabdomyolysis with Pravastatin

    Gemfibrozil

    Clinical Impact:

    There is an increased risk of myopathy/rhabdomyolysis when pravastatin is administered with gemfibrozil

    Intervention:

    Avoid concomitant use of gemfibrozil with pravastatin.

    Cyclosporine

    Clinical Impact:

    The risk of myopathy and rhabdomyolysis is increased with concomitant use of cyclosporine with pravastatin.

    Intervention:

    Initiate with a dosage of pravastatin sodium 10 mg once daily. Do not exceed pravastatin 20 mg once daily [see Dosage and Administration (2.5)].

    Select Macrolide Antibiotics

    Clinical Impact:

    The risk of myopathy and rhabdomyolysis is increased by concomitant use of clarithromycin or erythromycin with pravastatin. Other macrolides (e.g., azithromycin) have the potential to increase pravastatin exposures and increase the risk of myopathy and rhabdomyolysis when used concomitantly.

    Intervention:

    For patients taking erythromycin or clarithromycin, do not exceed 40 mg pravastatin once daily [see Dosage and Administration (2.5)].

    Niacin

    Clinical Impact:

    Cases of myopathy and rhabdomyolysis have been observed with concomitant use of niacin with pravastatin.

    Intervention:

    Consider if the benefit of using niacin concomitantly with pravastatin outweighs the increased risk of myopathy and rhabdomyolysis. If concomitant use is decided, monitor patients for signs and symptoms of myopathy, particularly during initiation of therapy and during upward dose titration of either drug.

    Fibrates (other than Gemfibrozil)

    Clinical Impact:

    Fibrates may cause myopathy when given alone. The risk of myopathy and rhabdomyolysis is increased with concomitant use of fibrates with pravastatin.

    Intervention:

    Consider if the benefit of using fibrates concomitantly with pravastatin outweighs the increased risk of myopathy and rhabdomyolysis. If concomitant use is decided, monitor patients for signs and symptoms of myopathy, particularly during initiation of therapy and during upward dose titration of either drug.

    Colchicine

    Clinical Impact:

    Cases of myopathy and rhabdomyolysis have been reported with concomitant use of colchicine with pravastatin.

    Intervention:

    Consider if the benefit of using colchicine concomitantly with pravastatin outweighs the increased risk of myopathy and rhabdomyolysis. If concomitant use is decided, monitor patients for signs and symptoms of myopathy, particularly during initiation of therapy and during upward dose titration of either drug.


    7.2 Drug Interactions that Decrease the Efficacy of Pravastatin

    Table 4 presents drug interactions that may decrease the efficacy of pravastatin and instructions for preventing or managing them.

    Table 4: Drug Interactions that Decrease the Efficacy of Pravastatin

    Bile Acid Sequestrants

    Clinical Impact:

    Concomitant cholestyramine or colestipol administration decreased the mean exposure of pravastatin approximately 51% and 47%, respectively [see Clinical Pharmacology (12.3)].

    Intervention:

    In patients taking a bile acid sequestrant, administer pravastatin at least 1 hour before or at least 4 hours after the bile acid sequestrant [see Dosage and Administration (2.5)].


  • 8 USE IN SPECIFIC POPULATIONS

    8.1 Pregnancy

    Risk Summary

    Discontinue pravastatin when pregnancy is recognized. Alternatively, consider the ongoing therapeutic needs of the individual patient. Pravastatin decreases synthesis of cholesterol and possibly other biologically active substances derived from cholesterol; therefore, pravastatin may cause fetal harm when administered to pregnant patients based on the mechanism of action [see Clinical Pharmacology (12.1)]. In addition, treatment of hyperlipidemia is not generally necessary during pregnancy. Atherosclerosis is a chronic process and the discontinuation of lipid-lowering drugs during pregnancy should have little impact on the outcome of long-term therapy of primary hyperlipidemia for most patients. Available data from case series and prospective and retrospective observational cohort studies over decades of use with statins in pregnant women have not identified a drug-associated risk of major congenital malformations. Published data from prospective and retrospective observational cohort studies with pravastatin use in pregnant women are insufficient to determine if there is a drug-associated risk of miscarriage (see Data). In animal reproduction studies, no evidence of fetal malformations was seen in pregnant rats or rabbits orally administered pravastatin during the period of organogenesis at doses that resulted in 10 times and 120 times, respectively, the human exposure at the maximum recommended human dose (MRHD) of 80 mg/day, based on body surface area (mg/m2). An imbalance in some fetal skeletal variations, increased offspring mortality, and developmental delays occurred when pregnant rats were exposed to 10 times to 12 times the MRHD during organogenesis to parturition (see Data).

    The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

    Data

    Human Data

    A Medicaid cohort linkage study of 1,152 statin-exposed pregnant women compared to 886,996 controls did not find a significant teratogenic effect from maternal use of statins in the first trimester of pregnancy, after adjusting for potential cofounders – including maternal age, diabetes mellitus, hypertension, obesity, and alcohol and tobacco use – using propensity score-based methods. The relative risk of congenital malformations between the group with statin use and the group with no statin use in the first trimester was 1.07 (95% confidence interval 0.85 to 1.37) after controlling for confounders, particularly pre-existing diabetes mellitus. There were also no statistically significant increases in any of the organ-specific malformations assessed after accounting for cofounders. In the majority of pregnancies, statin treatment was initiated prior to pregnancy and was discontinued at some point in the first trimester when pregnancy was identified. Study limitations include reliance on physician coding to define the presence of a malformation, lack of control for certain confounders such as body mass index, use of prescription dispensing as verification for the use of a statin, and lack of information on non-live births.

    Animal Data

    Embryofetal and neonatal mortality was observed in rats given pravastatin during the period of organogenesis or during organogenesis continuing through weaning. In pregnant rats given oral gavage doses of 4, 20, 100, 500, and 1,000 mg/kg/day from gestation days 7 through 17 (organogenesis) increased mortality of offspring and increased cervical rib skeletal anomalies were observed at ≥100 mg/kg/day systemic exposure, 10 times the human exposure at 80 mg/day MRHD based on body surface area (mg/m2).

    In other studies, no teratogenic effects were observed when pravastatin was dosed orally during organogenesis in rabbits (gestation days 6 through 18) up to 50 mg/kg/day or in rats (gestation days 7 through 17) up to
    1,000 mg/kg/day. Exposures were 10 times (rabbit) or 120 times (rat) the human exposure at 80 mg/day MRHD based on body surface area (mg/m2).

    In pregnant rats given oral gavage doses of 10, 100, and 1,000 mg/kg/day from gestation day 17 through lactation day 21 (weaning), developmental delays were observed at ≥100 mg/kg/day systemic exposure, corresponding to 12 times the human exposure at 80 mg/day MRHD, based on body surface area (mg/m2).

    In pregnant rats, pravastatin crosses the placenta and is found in fetal tissue at 30% of the maternal plasma levels following administration of a single dose of 20 mg/day orally on gestation day 18, which corresponds to exposure 2 times the MRHD of 80 mg daily based on body surface area (mg/m2).

    8.2 Lactation

    Risk Summary

    Based on one lactation study in published literature, pravastatin is present in human milk. There is no available information on the effects of the drug on the breastfed infant or the effects of the drug on milk production. Statins, including pravastatin, decrease cholesterol synthesis and possibly the synthesis of other biologically active substances derived from cholesterol and may cause harm to the breastfed infant.

    Because of the potential for serious adverse reactions in a breastfed infant, based on the mechanism of action, advise patients that breastfeeding is not recommended during treatment with pravastatin [see Use in Specific Populations (8.1), Clinical Pharmacology (12.1)].

    8.4 Pediatric use

    The safety and effectiveness of pravastatin as an adjunct to diet to reduce LDL-C have been established in pediatric patients 8 years of age and older with HeFH. Use of pravastatin for this indication is based on a double-blind, placebo-controlled clinical study in 214 pediatric patients (100 males and 114 females) 8 years of age and older with HeFH. Doses greater than 40 mg daily have not been studied in this population.

    The safety and effectiveness of pravastatin have not been established in pediatric patients younger than 10 years of age with HeFH or in pediatric patients with other types of hyperlipidemia (other than HeFH).

    8.5 Geriatric Use

    In clinical studies, 4,797 (36.4%) pravastatin-treated patients were aged 65 and older and 110 (0.8%) were aged 75 and older. No significant differences in efficacy or safety were observed between geriatric patients and younger patients.

    Mean pravastatin AUCs are 25% to 50% higher in elderly subjects than in healthy young subjects, but mean maximum plasma concentration (Cmax), time to maximum plasma concentration (Tmax), and half-life (t½) values are similar in both age groups and substantial accumulation of pravastatin would not be expected in the elderly [see Clinical Pharmacology (12.3)].

    Advanced age (≥65 years) is a risk factor for pravastatin-associated myopathy and rhabdomyolysis. Dose selection for an elderly patient should be cautious, recognizing the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy and the higher risk of myopathy. Monitor geriatric patients receiving pravastatin for the increased risk of myopathy [see Warnings and Precautions (5.1)].

    8.6 Renal Impairment

    Renal impairment is a risk factor for myopathy and rhabdomyolysis. Monitor all patients with renal impairment for development of myopathy.

    In patients with severe renal impairment, the recommended starting dose is pravastatin sodium 10 mg once daily. The maximum recommended dosage in patients with severe renal impairment is pravastatin 40 mg once daily. The recommended dosage for patients with mild or moderate renal impairment is the same as patients with normal renal function [see Dosage and Administration (2.4), Warnings and Precautions (5.1), Clinical Pharmacology (12.3)].

    8.7 Hepatic Impairment

    Pravastatin shows a large inter-subject variability in pharmacokinetics in patients with liver cirrhosis [Clinical Pharmacology (12.3)]. Pravastatin is contraindicated in patients with acute liver failure or decompensated cirrhosis [see Contraindications (4), Warnings and Precautions (5.3)].

  • 10 OVERDOSAGE

    No specific antidotes for pravastatin are known. Contact Poison Control (1-800-222-1222) for latest recommendations.

  • 11 DESCRIPTION

    Pravastatin sodium, USP is a statin, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase.

    Pravastatin sodium, USP is designated chemically as 1-Naphthalene-heptanoic acid, 1,2,6,7,8,8a-hexahydro-β,δ,6-trihydroxy-2-methyl-8-(2-methyl-1-oxobutoxy)-, monosodium salt, [1S- [1α(βS*,δS*),2α,6α,8β(R*),8aα]]-.

    Structural formula:

    pravastatin sodium structural formula

    C23H35NaO7 M.W. 446.52

    Pravastatin sodium, USP is an odorless, white to off-white, fine or crystalline powder. It is a relatively polar hydrophilic compound with a partition coefficient (octanol/water) of 0.59 at a pH of 7.0. It is soluble in methanol and water (>300 mg/mL), slightly soluble in isopropanol, and practically insoluble in acetone, acetonitrile, chloroform, and ether.

    Pravastatin sodium tablets, USP for oral use contain 10 mg, 20 mg and 40 mg pravastatin sodium USP, which is equivalent to 9.50 mg, 19.01 mg and 38.03 mg of pravastatin, respectively. Inactive ingredients include: calcium phosphate dibasic anhydrous, croscarmellose sodium, crospovidone, lactose anhydrous, microcrystalline cellulose, povidone and sodium stearyl fumarate. Additionally, the 10 mg tablet contains ferric oxide red; the 20 mg tablet contains ferric oxide yellow; and the 40 mg tablet contains FD&C Blue No. 1 Aluminum Lake and D&C Yellow No.10.

  • 12 CLINICAL PHARMACOLOGY

    12.1 Mechanism of Action

    Pravastatin is a reversible inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts HMG-CoA to mevalonate, a precursor of cholesterol.

    12.2 Pharmacodynamics

    Inhibition of HMG-CoA reductase by pravastatin accelerates the expression of LDL-receptors, followed by the uptake of LDL-C from blood to the liver, leading to a decrease in plasma LDL-C and total cholesterol. Sustained inhibition of cholesterol synthesis in the liver also decreases levels of very-low-density lipoproteins. The maximum LDL-C reduction of pravastatin is usually achieved by 4 weeks and is maintained after that.

    12.3 Pharmacokinetics

    Absorption

    Pravastatin is administered orally in the active form. Peak plasma pravastatin concentrations occurred 1 to 1.5 hours upon oral administration. Based on urinary recovery of total radiolabeled drug, the average oral absorption of pravastatin is 34% and absolute bioavailability is 17%. While the presence of food in the gastrointestinal tract reduces area under the concentration-time curve (AUC) and Cmax by 31% and 49%, respectively, the lipid-lowering effects of the drug are similar whether taken with or 1 hour prior to meals.

    Pravastatin plasma concentrations, including AUC, Cmax, and steady-state minimum (Cmin), are directly proportional to administered dose. Systemic bioavailability of pravastatin administered following a bedtime dose was decreased 60% compared to that following an AM dose. Despite this decrease in systemic bioavailability, the efficacy of pravastatin administered once daily in the evening, although not statistically significant, was marginally more effective than that after a morning dose.

    The coefficient of variation (CV), based on between-subject variability, was 50% to 60% for AUC.

    The geometric means of pravastatin Cmax and AUC following a 20 mg dose in the fasted state were 26.5 ng/mL and 59.8 ng*hr/mL, respectively.

    Steady-state AUCs, Cmax, and Cmin plasma concentrations showed no evidence of pravastatin accumulation following once or twice daily administration of pravastatin sodium tablets.

    Distribution

    Approximately 50% of the circulating drug is bound to plasma proteins.

    Elimination

    Metabolism

    The major biotransformation pathways for pravastatin are: (a) isomerization to 6-epi pravastatin and the 3α-hydroxy isomer of pravastatin (SQ 31,906) and (b) enzymatic ring hydroxylation to SQ 31,945. The
    3α-hydroxy isomeric metabolite (SQ 31,906) has 1/10 to 1/40 the HMG-CoA reductase inhibitory activity of the parent compound. Pravastatin undergoes extensive first-pass extraction in the liver (extraction ratio 0.66).

    Excretion

    Approximately 20% of a radiolabeled oral dose is excreted in urine and 70% in the feces. After intravenous administration of radiolabeled pravastatin to normal volunteers, approximately 47% of total body clearance was via renal excretion and 53% by non-renal routes (i.e., biliary excretion and biotransformation).

    Following single dose oral administration of 14C-pravastatin, the radioactive elimination t½ for pravastatin is 1.8 hours in humans and the elimination half-life (t½) for total radioactivity (pravastatin plus metabolites) is 77 hours.

    Specific Populations

    Renal Impairment

    A single 20 mg oral dose of pravastatin was administered to 24 patients with varying degrees of renal impairment (as determined by creatinine clearance). No effect was observed on the pharmacokinetics of pravastatin or its 3α-hydroxy isomeric metabolite (SQ 31,906). Compared to healthy subjects with normal renal function, patients with severe renal impairment had 69% and 37% higher mean AUC and Cmax values, respectively, and a 0.61 hour shorter t½ for the inactive enzymatic ring hydroxylation metabolite (SQ 31,945) [see Use in Specific Populations (8.6)].

    Hepatic Impairment

    In a study comparing the kinetics of pravastatin in patients with biopsy confirmed cirrhosis (N=7) and normal subjects (N=7), the mean AUC varied 18-fold in cirrhotic patients and 5-fold in healthy subjects. Similarly, the peak pravastatin values varied 47-fold for cirrhotic patients compared to 6-fold for healthy subjects [see Use in Specific Populations (8.6)].

    Geriatric

    In a single oral dose study using pravastatin 20 mg, the mean AUC for pravastatin was approximately 27% greater and the mean cumulative urinary excretion (CUE) approximately 19% lower in elderly men (65 to 75 years old) compared with younger men (19 to 31 years old). In a similar study conducted in women, the mean AUC for pravastatin was approximately 46% higher and the mean CUE approximately 18% lower in elderly women (65 to 78 years old) compared with younger women (18 to 38 years old). In both studies, Cmax, Tmax, and t½ values were similar in older and younger subjects [see Use in Specific Populations (8.5)].

    Pediatric

    After 2 weeks of once-daily 20 mg oral pravastatin administration, the geometric means of AUC were 80.7 (CV 44%) and 44.8 (CV 89%) ng*hr/mL for pediatric patients 8 to 11 years (N=14) and 12 to 16 years (N=10), respectively. The corresponding values for Cmax were 42.4 (CV 54%) and 18.6 ng/mL (CV 100%) for pediatric patients 8 to 11 years and 12 to 16 years, respectively. No conclusion can be made based on these findings due to the small number of samples and large variability [see Use in Specific Populations (8.4)].

     

    Drug-Drug Interactions

    Table 5: Effect of Coadministered Drugs on the Pharmacokinetics of Pravastatin

    Coadministered Drug and Dosing Regimen

    Pravastatin

    Dose (mg)

    Change in AUC

    Change in Cmax

    Cyclosporine 5 mg/kg single dose

    40 mg single dose

    ↑282%

    ↑327%

    Clarithromycin 500 mg BID for 9 days

    40 mg OD for 8 days

    ↑110%

    ↑128%

    Boceprevir 800 mg TID for 6 days

    40 mg single dose

    ↑63%

    ↑49%

    Darunavir 600 mg BID/Ritonavir 100 mg BID for 7 days

    40 mg single dose

    ↑81%

    ↑63%

    Colestipol 10 g single dose

    20 mg single dose

    ↓47%

    ↓53%

    Cholestyramine 4 g single dose

    20 mg single dose

    Administered simultaneously

    ↓40%

    ↓39%

    Administered 1 hour prior to

    ↑12%

    ↑30%

    cholestyramine

    Administered 4 hours after

    ↓12%

    ↓6.8%

    cholestyramine

    Cholestyramine 24 g OD for 4 weeks

    20 mg BID for 8 weeks

    ↓51%

    ↑4.9%

    5 mg BID for 8 weeks

    ↓38%

    ↑23%

    10 mg BID for 8 weeks

    ↓18%

    ↓33%

    Fluconazole

    200 mg IV for 6 days

    20 mg PO+10 mg IV

    ↓34%

    ↓33%

    200 mg PO for 6 days

    20 mg PO+10 mg IV

    ↓16%

    ↓16%

    Kaletra 400 mg/100 mg BID for 14 days

    20 mg OD for 4 days

    ↑33%

    ↑26%

    Verapamil IR 120 mg for 1 day and Verapamil ER 480 mg for 3 days

    40 mg single dose

    ↑31%

    ↑42%

    Cimetidine 300 mg QID for 3 days

    20 mg single dose

    ↑30%

    ↑9.8%

    Antacids 15 mL QID for 3 days

    20 mg single dose

    ↓28%

    ↓24%

    Digoxin 0.2 mg OD for 9 days

    20 mg OD for 9 days

    ↑23%

    ↑26%

    Probucol 500 mg single dose

    20 mg single dose

    ↑14%

    ↑24%

    Warfarin 5 mg OD for 6 days

    20 mg BID for 6 days

    ↓13%

    ↑6.7%

    Itraconazole 200 mg OD for 30 days

    40 mg OD for 30 days

    ↑11% (compared to Day 1)

    ↑17% (compared to Day 1)

    Gemfibrozil 600 mg single dose

    20 mg single dose

    ↓7.0%

    ↓20%

    Aspirin 324 mg single dose

    20 mg single dose

    ↑4.7%

    ↑8.9%

    Niacin 1 g single dose

    20 mg single dose

    ↓3.6%

    ↓8.2%

    Diltiazem

    20 mg single dose

    ↑2.7%

    ↑30%

    Grapefruit juice

    40 mg single dose

    ↓1.8%

    ↑3.7%

    BID = twice daily; OD = once daily; QID = four times daily

    Table 6: Effect of Pravastatin on the Pharmacokinetics of Coadministered Drugs

    Pravastatin Dosing Regimen

    Name and Dose

    Change in AUC

    Change in Cmax

    20 mg BID for 6 days

    Warfarin 5 mg OD for 6 days Change in mean prothrombin time

    ↑17%

    ↑0.4 sec

    ↑15%

    20 mg OD for 9 days

    Digoxin 0.2 mg OD for 9 days

    ↑4.6%

    ↑5.3%

    20 mg BID for 4 weeks

    10 mg BID for 4 weeks

    5 mg BID for 4 weeks

    Antipyrine 1.2 g single dose

    ↑3.0%

    ↑1.6%

    ↑Less than 1%

    Not Reported

    20 mg OD for 4 days

    Kaletra 400 mg/100 mg BID for
    14 days

    No change

    No change

    BID = twice daily; OD = once daily


  • 13 NONCLINICAL TOXICOLOGY

    13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

    In a 2-year study in rats fed pravastatin at doses of 10, 30, or 100 mg/kg body weight, there was an increased incidence of hepatocellular carcinomas in males at the highest dose (p<0.01). These effects in rats were observed at approximately 12 times the human dose (HD) of 80 mg based on body surface area (mg/m2) and at approximately 4 times the HD, based on AUC.

    In a 2-year study in mice fed pravastatin at doses of 250 and 500 mg/kg/day, there was an increased incidence of hepatocellular carcinomas in males and females at both 250 and 500 mg/kg/day (p<0.0001). At these doses, lung adenomas in females were increased (p=0.013). These effects in mice were observed at approximately 15 times (250 mg/kg/day) and 23 times (500 mg/kg/day) the HD of 80 mg, based on AUC. In another 2-year study in mice with doses up to 100 mg/kg/day (producing drug exposures approximately 2 times the HD of 80 mg, based on AUC), there were no drug-induced tumors.

    No evidence of mutagenicity was observed in vitro, with or without rat-liver metabolic activation, in the following studies: microbial mutagen tests, using mutant strains of Salmonella typhimurium or Escherichia coli; a forward mutation assay in L5178Y TK +/- mouse lymphoma cells; a chromosomal aberration test in hamster cells; and a gene conversion assay using Saccharomyces cerevisiae. In addition, there was no evidence of mutagenicity in either a dominant lethal test in mice or a micronucleus test in mice.

    In a fertility study in adult rats with daily doses up to 500 mg/kg, pravastatin did not produce any adverse effects on fertility or general reproductive performance. No adverse effects were seen in juvenile rats dosed with 5 mg/kg/day pravastatin (5 times plasma exposure at the maximum recommended human dose [MRHD] of 80 mg based on AUC) in a study of pravastatin administered from postnatal days (PND) 4 through 80 at 5, 15 and 45 mg/kg/day. A PND 4 rat is generally comparable to a 3rd trimester human fetus with regards to neurologic development/myelination. At ≥15 mg/kg/day (≥20 times the MRHD), decreased body-weight gain was observed during the pre-weaning period and slight thinning of the corpus callosum was observed at the end of the drug-free recovery period (PND 132). Thinning of the corpus callosum was not associated with any inflammatory or degenerative changes in the brain. Impacts on neurobehavioral and learning endpoints were detected only at very high exposures (43 times the MRHD). No thinning of the corpus callosum was observed in rats dosed with pravastatin for 3 months beginning on PND 35 at ≥250 mg/kg/day. PND 35 in a rat is approximately equivalent to an 8 to 12-year-old human child.

  • 14 CLINICAL STUDIES

    Prevention of Coronary Heart Disease

    In the Pravastatin Primary Prevention Study (WOS), the effect of pravastatin on fatal and nonfatal CHD was assessed in 6,595 male patients 45 to 64 years of age, without a previous MI, and with LDL-C levels between 156 to 254 mg/dL. In this randomized, double-blind, placebo-controlled study, patients were treated with standard care, including dietary advice, and either pravastatin 40 mg daily (N=3,302) or placebo (N=3,293) and followed for a median duration of 4.8 years. Median (25th, 75th percentile) percent changes from baseline after 6 months of pravastatin treatment in Total-C, LDL-C, TG, and HDL-C were -20.3 (-26.9, -11.7), -27.7 (-36.0, -16.9), -9.1 (-27.6, 12.5), and 6.7 (-2.1, 15.6), respectively.

    Pravastatin significantly reduced the rate of first coronary events (either CHD death or nonfatal MI) by 31% (248 events in the placebo group [CHD death=44, nonfatal MI=204] versus 174 events in the pravastatin group [CHD death=31, nonfatal MI=143], p=0.0001 [see figure below]). The risk reduction with pravastatin was similar across the age range studied and throughout the range of baseline LDL cholesterol levels.

    1

    Pravastatin also decreased the risk for undergoing myocardial revascularization procedures (coronary artery bypass graft [CABG] surgery or percutaneous transluminal coronary angioplasty [PTCA]) by 37% (80 vs 51 patients). Cardiovascular deaths were decreased by 32% (73 vs 50) and there was no increase in death from non-cardiovascular causes.

    Secondary Prevention of Cardiovascular Events

    In the LIPID study, the effect of pravastatin, 40 mg daily, was assessed in 9,014 patients (7,498 men; 1,516 women; 3,514 patients ≥65 years; 782 patients with diabetes) who had experienced either an MI (5,754 patients) or had been hospitalized for unstable angina pectoris (3,260 patients) in the preceding 3 to 36 months. Patients in this multicenter, double-blind, placebo-controlled study participated for an average of 5.6 years (median of 5.9 years) and at randomization had Total-C between 114 and 563 mg/dL (mean 219 mg/dL), LDL-C between 46 and 274 mg/dL (mean 150 mg/dL), TG between 35 and 2,710 mg/dL (mean 160 mg/dL), and HDL-C between 1 and 103 mg/dL (mean 37 mg/dL). At baseline, 82% of patients were receiving aspirin and 76% were receiving antihypertensive medication. Treatment with pravastatin significantly reduced the risk for total mortality by reducing coronary death (see Table 7). The risk reduction due to treatment with pravastatin on CHD mortality was consistent regardless of age. Pravastatin significantly reduced the risk for total mortality (by reducing CHD death) and CHD events (CHD mortality or nonfatal MI) in patients who qualified with a history of either MI or hospitalization for unstable angina pectoris.

    Table 7: LIPID - Primary and Secondary Endpoints

    Number (%) of Subjects

    Event

    Pravastatin 40 mg
    (N=4,512)

    Placebo
    (N=4,502)

    Risk Reduction

    p-value

    Primary Endpoint

    CHD mortality

    287 (6.4)

    373 (8.3)

    24%

    0.0004

    Secondary Endpoints

    Total mortality

    498 (11.0)

    633 (14.1)

    23%

    <0.0001

    CHD mortality or nonfatal MI

    557 (12.3)

    715 (15.9)

    24%

    <0.0001

    Myocardial revascularization
    procedures (CABG or PTCA)

    584 (12.9)

    706 (15.7)

    20%

    <0.0001

    Stroke

    All-cause

    169 (3.7)

    204 (4.5)

    19%

    0.0477

    Non-hemorrhagic

    154 (3.4)

    196 (4.4)

    23%

    0.0154

    Cardiovascular mortality

    331 (7.3)

    433 (9.6)

    25%

    <0.0001

    In the CARE study, the effect of pravastatin, 40 mg daily, on CHD death and nonfatal MI was assessed in 4,159 patients (3,583 men and 576 women) who had experienced a MI in the preceding 3 to 20 months and who had normal (below the 75th percentile of the general population) plasma total cholesterol levels. Patients in this double-blind, placebo-controlled study participated for an average of 4.9 years and had a mean baseline Total-C of 209 mg/dL. LDL-C levels in this patient population ranged from 101 to 180 mg/dL (mean 139 mg/dL). At baseline, 84% of patients were receiving aspirin and 82% were taking antihypertensive medications. Median (25th, 75th percentile) percent changes from baseline after 6 months of pravastatin treatment in Total-C, LDL-C, TG, and HDL-C were -22.0 (-28.4, -14.9), -32.4 (-39.9, -23.7), -11.0 (-26.5, 8.6), and 5.1 (-2.9, 12.7), respectively. Treatment with pravastatin significantly reduced the rate of first recurrent coronary events (either CHD death or nonfatal MI), the risk of undergoing revascularization procedures (PTCA, CABG), and the risk for stroke or TIA (see Table 8).

    Table 8: CARE - Primary and Secondary Endpoints

    Number (%) of Subjects

    Event

    Pravastatin 40 mg
    (N=2,081)

    Placebo
    (N=2,078)

    Risk Reduction

    p-value

    Primary Endpoint

    CHD mortality or nonfatal MIa

    212 (10.2)

    274 (13.2)

    24%

    0.003

    Secondary Endpoints

    Myocardial revascularization
    procedures (CABG or PTCA)

    294 (14.1)

    391 (18.8)

    27%

    <0.001

    Stroke or TIA

    93 (4.5)

    124 (6.0)

    26%

    0.029

    a The risk reduction due to treatment with pravastatin was consistent in both sexes.

    Primary Hyperlipidemia

    In multicenter, double-blind, placebo-controlled studies of patients with primary hyperlipidemia, treatment with pravastatin in daily doses ranging from 10 to 40 mg consistently and significantly decreased Total-C, LDL-C, and TG (see Table 9).

    In a pooled analysis of 2 multicenter, double-blind, placebo-controlled studies of patients with primary hyperlipidemia, treatment with pravastatin at a daily dose of 80 mg (N=277) significantly decreased Total-C, LDL-C, and TG. The 25th and 75th percentile changes from baseline in LDL-C for pravastatin 80 mg were -43% and -30%. The efficacy results of the individual studies were consistent with the pooled data (see Table 9).

    Table 9: Primary Hyperlipidemia Trials: Dose Response of Pravastatin Once Daily Administration

    Dose

    Total-C

    LDL-C

    HDL-C

    TG

    Mean Percent Changes From Baseline After 8 Weeksa

    Placebo (N=36)

    -3%

    -4%

    +1%

    -4%

    10 mg (N=18)

    -16%

    -22%

    +7%

    -15%

    20 mg (N=19)

    -24%

    -32%

    +2%

    -11%

    40 mg (N=18)

    -25%

    -34%

    +12%

    -24%

    Mean Percent Changes From Baseline After 6 Weeksb

    Placebo (N=162)

    0%

    -1%

    -1%

    +1%

    80 mg (N=277)

    -27%

    -37%

    +3%

    -19%

    a A multicenter, double-blind, placebo-controlled study.

    b Pooled analysis of 2 multicenter, double-blind, placebo-controlled studies.

    Hypertriglyceridemia

    The response to pravastatin in patients with hypertriglyceridemia (baseline TG >200 mg/dL and LDL-C <160 mg/dL) was evaluated in a subset of 429 patients from the CARE study. For pravastatin-treated subjects, the median (min, max) baseline TG level was 246.0 (200.5, 349.5) mg/dL (see Table 10).

    Table 10: Patients with Hypertriglyceridemia Median (25th, 75th percentile) % Change from Baseline

    Pravastatin 40 mg (N=429)

    Placebo (N=430)

    TG

    -21.1 (-34.8, 1.3)

    -6.3 (-23.1, 18.3)

    Total-C

    -22.1 (-27.1, -14.8)

    0.2 (-6.9, 6.8)

    LDL-C

    -31.7 (-39.6, -21.5)

    0.7 (-9.0, 10.0)

    HDL-C

    7.4 (-1.2, 17.7)

    2.8 (-5.7, 11.7)

    Non-HDL-C

    -27.2 (-34.0, -18.5)

    -0.8 (-8.2, 7.0)

    Dysbetalipoproteinemia

    The response to pravastatin in two double-blind crossover studies of 46 patients with genotype E2/E2 and dysbetalipoproteinemia is shown in Table 11.

    Table 11: Patients with Dysbetalipoproteinemia Median (min, max) % Change from Baseline

    Median (min, max)
    at Baseline (mg/dL)

    Median % Change (min, max)

    Pravastatin 40 mg (N=20)

    Study 1

    Total-C

    386.5 (245.0, 672.0)

    -32.7 (-58.5, 4.6)

    TG

    443.0 (275.0, 1299.0)

    -23.7 (-68.5, 44.7)

    VLDL-Ca

    206.5 (110.0, 379.0)

    -43.8 (-73.1, -14.3)

    LDL-Ca

    117.5 (80.0, 170.0)

    -40.8 (-63.7, 4.6)

    HDL-C

    30.0 (18.0, 88.0)

    6.4 (-45.0, 105.6)

    Non-HDL-C

    344.5 (215.0, 646.0)

    -36.7 (-66.3, 5.8)

    a N=14

    Median (min, max)
    at Baseline (mg/dL)

    Median % Change (min, max)

    Pravastatin 40 mg (N=26)

    Study 2

    Total-C

    340.3 (230.1, 448.6)

    -31.4 (-54.5, -13.0)

    TG

    343.2 (212.6, 845.9)

    -11.9 (-56.5, 44.8)

    VLDL-C

    145.0 (71.5, 309.4)

    -35.7 (-74.7, 19.1)

    LDL-C

    128.6 (63.8, 177.9)

    -30.3 (-52.2, 13.5)

    HDL-C

    38.7 (27.1, 58.0)

    5.0 (-17.7, 66.7)

    Non-HDL-C

    295.8 (195.3, 421.5)

    -35.5 (-81.0, -13.5)

    HeFH in Pediatric Patients Aged 8 Years and Above

    A double-blind, placebo-controlled study in 214 pedatric patients (100 males and 114 females) with heterozygous familial hypercholesterolemia (HeFH), aged 8 to 18 years was conducted for 2 years. The pediatric patients aged 8 to 13 years were randomized to placebo (N=63) or 20 mg of pravastatin daily (N=65) and the pediatric patients aged 14 to 18 years were randomized to placebo (N=45) or 40 mg of pravastatin daily (N=41). Inclusion in the study required an LDL-C level >95th percentile for age and sex and one parent with either a clinical or molecular diagnosis of familial hypercholesterolemia. The mean baseline LDL-C value was 239 mg/dL and 237 mg/dL in the pravastatin (range: 151 to 405 mg/dL) and placebo (range: 154 to 375 mg/dL) groups, respectively.

    Pravastatin significantly decreased plasma levels of LDL-C, Total-C, and ApoB in both pediatric age groups (see Table 12). The effect of pravastatin treatment in the 2 age groups was similar.

    Table 12: Lipid-Lowering Effects of Pravastatin in Pediatric Patients with Heterozygous Familial Hypercholesterolemia: Least-Squares Mean % Change from Baseline at Month 24 (Last Observation Carried Forward: Intent-to-Treat)a

    Pravastatin

    20 mg

    (Aged 8 to 13 years) N=65

    Pravastatin

    40 mg

    (Aged 14 to 18 years) N=41

    Combined Pravastatin (Aged 8 to 18 years) N=106

    Combined Placebo (Aged 8 to 18 years) N=108

    95% CI of the Difference Between Combined Pravastatin and Placebo

    LDL-C

    -26.04b

    -21.07b

    -24.07b

    -1.52

    (-26.74, -18.86)

    TC

    -20.75b

    -13.08b

    -17.72b

    -0.65

    (-20.40, -13.83)

    HDL-C

    1.04

    13.71

    5.97

    3.13

    (-1.71, 7.43)

    TG

    -9.58

    -0.30

    -5.88

    -3.27

    (-13.95, 10.01)

    ApoB (N)

    -23.16b

    (61)

    -18.08b

    (39)

    -21.11b

    (100)

    -0.97

    (106)

    (-24.29, -16.18)

    a The above least-squares mean values were calculated based on log-transformed lipid values.

    b Significant at p≤0.0001 when compared with placebo.

    The mean achieved LDL-C was 186 mg/dL (range: 67 to 363 mg/dL) in the pravastatin group k to 236 mg/dL (range: 105 to 438 mg/dL) in the placebo group.


  • 16 HOW SUPPLIED/STORAGE AND HANDLING

    16.1 How Supplied

    Pravastatin sodium tablets, USP are supplied as:

    10 mg tablets: Pink, unscored, round tablet, debossed “TEVA” on one side and “771” on the other side in bottles of 90 (NDC 0093-0771-98) and 1000 (NDC 0093-0771-10).

    20 mg tablets: Light-yellow, unscored, round tablet, debossed “TEVA” on one side and “7201” on the other side in bottles of 90 (NDC 0093-7201-98) and 1000 (NDC 0093-7201-10).

    40 mg tablets: Light-green, unscored, round tablet, debossed “TEVA” on one side and “7202” on the other side in bottles of 90 (NDC 0093-7202-98) and 1000 (NDC 0093-7202-10).

    Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature]. Protect from moisture. Protect from light.

    Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required).

    Keep this and all medications out of the reach of children.

  • 17 PATIENT COUNSELING INFORMATION

    Myopathy and Rhabdomyolysis

    Advise patients that pravastatin sodium tablets may cause myopathy and rhabdomyolysis. Inform patients that the risk is increased when taking certain types of medication and they should discuss all medication, both prescription and over the counter, with their healthcare provider. Instruct patients to promptly report any unexplained muscle pain, tenderness or weakness particularly if accompanied by malaise or fever [see Warnings and Precautions (5.1)Drug Interactions (7.1)].

    Hepatic Dysfunction

    Inform patients that pravastatin sodium tablets may cause liver enzyme elevations and possibly liver failure. Advise patients to promptly report fatigue, anorexia, right upper abdominal discomfort, dark urine or jaundice [see Warnings and Precautions (5.3)].

    Increases in HbA1c and Fasting Serum Glucose Levels

    Inform patients that increases in HbA1c and fasting serum glucose levels may occur with pravastatin sodium tablets. Encourage patients to optimize lifestyle measures, including regular exercise, maintaining a healthy body weight, and making healthy food choices [see Warnings and Precautions (5.4)].

    Pregnancy

    Advise pregnant patients and patients who may become pregnant of the potential risk to a fetus. Advise patients to inform their healthcare provider of a known or suspected pregnancy to discuss if pravastatin sodium tablets should be discontinued [see Use in Specific Populations (8.1)].

    Lactation

    Advise patients that breastfeeding is not recommended during treatment with pravastatin sodium tablets [see Use in Specific Populations (8.2)].

    Manufactured In Czech Republic By:

    Teva Czech Industries, s.r.o.

    Opava-Komarov, Czech Republic

    Manufactured For:
    Teva Pharmaceuticals
    Parsippany, NJ 07054

    Rev. AA 8/2022

  • PRINCIPAL DISPLAY PANEL

    NDC 0093-0771-98
    Pravastatin Sodium Tablets, USP
    10 mg
    Rx only
    90 Tablets

    10 mg new label

  • PRINCIPAL DISPLAY PANEL

    NDC 0093-7201-98
    Pravastatin Sodium Tablets, USP
    20 mg
    Rx only
    90 TABLETS

    20 mg new

  • PRINCIPAL DISPLAY PANEL

    NDC 0093-7202-98
    Pravastatin Sodium Tablets, USP
    40 mg
    Rx only
    90 TABLETS

    40 mg new

  • INGREDIENTS AND APPEARANCE
    PRAVASTATIN SODIUM 
    pravastatin sodium tablet
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:0093-0771
    Route of AdministrationORAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    PRAVASTATIN SODIUM (UNII: 3M8608UQ61) (PRAVASTATIN - UNII:KXO2KT9N0G) PRAVASTATIN SODIUM10 mg
    Inactive Ingredients
    Ingredient NameStrength
    ANHYDROUS DIBASIC CALCIUM PHOSPHATE (UNII: L11K75P92J)  
    CROSPOVIDONE (15 MPA.S AT 5%) (UNII: 68401960MK)  
    ANHYDROUS LACTOSE (UNII: 3SY5LH9PMK)  
    CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D61U)  
    POVIDONE K30 (UNII: U725QWY32X)  
    CROSCARMELLOSE SODIUM (UNII: M28OL1HH48)  
    FERRIC OXIDE RED (UNII: 1K09F3G675)  
    SODIUM STEARYL FUMARATE (UNII: 7CV7WJK4UI)  
    Product Characteristics
    ColorpinkScoreno score
    ShapeROUNDSize7mm
    FlavorImprint Code TEVA;771
    Contains    
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:0093-0771-9890 in 1 BOTTLE; Type 0: Not a Combination Product04/25/2006
    2NDC:0093-0771-101000 in 1 BOTTLE; Type 0: Not a Combination Product03/07/2008
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA07605604/25/2006
    PRAVASTATIN SODIUM 
    pravastatin sodium tablet
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:0093-7201
    Route of AdministrationORAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    PRAVASTATIN SODIUM (UNII: 3M8608UQ61) (PRAVASTATIN - UNII:KXO2KT9N0G) PRAVASTATIN SODIUM20 mg
    Inactive Ingredients
    Ingredient NameStrength
    ANHYDROUS DIBASIC CALCIUM PHOSPHATE (UNII: L11K75P92J)  
    CROSPOVIDONE (15 MPA.S AT 5%) (UNII: 68401960MK)  
    ANHYDROUS LACTOSE (UNII: 3SY5LH9PMK)  
    CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D61U)  
    POVIDONE K30 (UNII: U725QWY32X)  
    CROSCARMELLOSE SODIUM (UNII: M28OL1HH48)  
    SODIUM STEARYL FUMARATE (UNII: 7CV7WJK4UI)  
    FERRIC OXIDE YELLOW (UNII: EX438O2MRT)  
    Product Characteristics
    Coloryellow (light-yellow) Scoreno score
    ShapeROUNDSize8mm
    FlavorImprint Code TEVA;7201
    Contains    
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:0093-7201-9890 in 1 BOTTLE; Type 0: Not a Combination Product04/25/2006
    2NDC:0093-7201-101000 in 1 BOTTLE; Type 0: Not a Combination Product04/25/2006
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA07605604/25/2006
    PRAVASTATIN SODIUM 
    pravastatin sodium tablet
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:0093-7202
    Route of AdministrationORAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    PRAVASTATIN SODIUM (UNII: 3M8608UQ61) (PRAVASTATIN - UNII:KXO2KT9N0G) PRAVASTATIN SODIUM40 mg
    Inactive Ingredients
    Ingredient NameStrength
    ANHYDROUS DIBASIC CALCIUM PHOSPHATE (UNII: L11K75P92J)  
    CROSPOVIDONE (15 MPA.S AT 5%) (UNII: 68401960MK)  
    ANHYDROUS LACTOSE (UNII: 3SY5LH9PMK)  
    CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D61U)  
    POVIDONE K30 (UNII: U725QWY32X)  
    CROSCARMELLOSE SODIUM (UNII: M28OL1HH48)  
    SODIUM STEARYL FUMARATE (UNII: 7CV7WJK4UI)  
    FD&C BLUE NO. 1 (UNII: H3R47K3TBD)  
    D&C YELLOW NO. 10 (UNII: 35SW5USQ3G)  
    Product Characteristics
    Colorgreen (light-green) Scoreno score
    ShapeROUNDSize10mm
    FlavorImprint Code TEVA;7202
    Contains    
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:0093-7202-9890 in 1 BOTTLE; Type 0: Not a Combination Product04/25/2006
    2NDC:0093-7202-101000 in 1 BOTTLE; Type 0: Not a Combination Product04/25/2006
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA07605604/25/2006
    Labeler - Teva Pharmaceuticals USA, Inc. (001627975)